Rakovina Therapeutics 2024 AI Cancer Drug Discovery Investor Presentation

Rakovina Therapeutics uses its proprietary Deep Docking AI platform to rapidly screen billions of molecular structures for targeted cancer drug candidates, focusing on DNA-damage response vulnerabilities. Founded in 2021, the company leverages advanced AI algorithms and established R&D infrastructure in collaboration with the University of British Columbia to accelerate therapeutic development.